SCIT with the marketed dose of high-dose HDM allergoid was well tolerated in clinical development and in daily practice. There was no increased risk for the investigated patient subgroups. Tolerability was comparable to HDM sublingual immunotherapy (SLIT) tablets.
Keyphrases
- high dose
- clinical trial
- stem cell transplantation
- low dose
- primary care
- healthcare
- physical activity
- allergic rhinitis
- open label
- electronic health record
- case report
- phase iii
- double blind
- atomic force microscopy
- human health
- health risk assessment
- machine learning
- mass spectrometry
- drinking water
- single molecule
- high speed